CBX-12 is under clinical development by Cybrexa and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II drugs for Gallbladder Cancer have a 32% phase transition success ...
peptide drug conjugates (PDC) and multi-functional peptide conjugates (MPC) across an extensive global network of discovery and development partners. PeptiDream is headquartered in Kawasaki ...
Ke Hou generated a compound that prevents tau aggregation in the murine brain, but the potential Alzheimer’s disease therapy ...
providing unrivalled access to 30+ speakers discussing innovation and development in bispecific-drug conjugates, antibody-oligonucleotide conjugates, peptide-drug conjugates plus many other novel ...
Our approach is noteworthy for its ability to exclusively functionalize the N-terminus of peptides, irrespective of lysine ...
In recent years, several ADC drugs have achieved sales exceeding 1 billion USD, drawing significant market attention. This rise in ADC drug ...
R&D Daily丨DaShi Pharmaceutical's first IND application for a new antibody drug targeting NGF was accepted ChK1 inhibitor!
In this interview, Grace Liu from Sino Biological shares her expertise on Antibody-Drug Conjugates (ADCs), a revolutionary cancer therapy combining precision targeting with potent cytotoxic drugs.
INR:2922. crypto casino without kyc East Sunshine Pharmaceutical to win 1.5 billion antithrombotic drug Precision-guided myeloma drug! Melflufen, the fi ...
INR:9130. delhi satta 2020 chart “First-in-class” peptide-drug conjugate receives accelerated approval from FDA eLife: Asthma may increase the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback